The primary patent for Lantus (insulin glargine) expired in December 2014 [1]. However, additional patents and exclusivities may have extended market protection for the drug for a longer period [2].
When did Lantus lose its main patent protection?
Lantus, a long-acting insulin analog used to treat diabetes, had its key patent expire in December 2014 [1]. This marked the beginning of potential market entry for generic versions of insulin glargine.
Are there other patents that affect Lantus exclusivity?
Beyond the initial patent, other patents related to Lantus's formulation, manufacturing processes, and methods of use may have been in effect [2]. These could have provided further market exclusivity for Sanofi, the drug's manufacturer. DrugPatentWatch.com tracks these types of patent expirations and exclusivities [2].
What happens after a drug patent expires?
Once a primary patent expires, it typically opens the door for generic manufacturers to seek approval to market their versions of the drug. These generic drugs are usually bioequivalent to the brand-name product and are offered at a lower cost [3].
When did biosimilars for Lantus become available?
While the main patent expired in 2014, the availability of biosimilars for insulin glargine, such as Basaglar and Semglee, was later than anticipated due to patent litigation and regulatory pathways [4]. These biosimilars entered the market years after the initial patent expiration.
Who makes the generic or biosimilar versions of Lantus?
Several companies have developed and market biosimilar versions of insulin glargine. Eli Lilly and Company markets Basaglar, and Viatris (in partnership with Biocon) markets Semglee, among others [5][6].
How do biosimilars for Lantus compare to the original?
Biosimilars are highly similar to the reference biologic product, meaning they are expected to have the same safety, efficacy, and quality. They undergo rigorous testing to demonstrate this similarity. For insulin glargine, biosimilars offer a more affordable alternative to Lantus [4][6].
What is the cost difference between Lantus and its biosimilars?
Biosimilar insulins generally offer significant cost savings compared to the reference product, Lantus. This price reduction is a primary driver for their adoption in the market, aiming to reduce healthcare expenditures for diabetes management [4][6].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.fda.gov/drugs/generic-drugs
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305058/
[5] https://www.drugs.com/principals/insulin-glargine.html
[6] https://www.biosimilarssolutions.com/biosimilar-insulin-glargine